Skip to main content

Table 3 Clinical and demographic characteristics of patients receiving disease-modifying anti-rheumatic treatment with methotrexate or having no disease-modifying anti-rheumatic drug (DMARD) treatment

From: Decreased levels of soluble receptor for advanced glycation end products in patients with rheumatoid arthritis indicating deficient inflammatory control

Characteristic

Methotrexate treated

No DMARD

Patients (n)

19

26

Age (years ± standard deviation)

63.8 ± 14.3

60.8 ± 14.0

Sex (male/female)

5/14

8/18

Disease duration (years ± standard deviation)

13.1 ± 9.6*

8.2 ± 8.3

Rheumatoid factor (+/-)

12/7

14/12

Radiographic data (erosive/non-erosive)

15/4*

10/16

  1. * P < 0.05 as compared with patients without DMARD treatment.